Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype–phenotype correlations in FBN1 exons 24–40

Mutations in the gene for fibrillin-1 (FBN1) cause Marfan syndrome, an autosomal dominant disorder of connective tissue with prominent manifestations in the skeletal, ocular, and cardiovascular system. There is a remarkable degree of clinical variability both within and between families with Marfan syndrome as well as in individuals with related disorders of connective tissue caused by FBN1 mutations and collectively termed type-1 fibrillinopathies. The so-called neonatal region in FBN1 exons 24–32 comprises one of the few generally accepted genotype–phenotype correlations described to date. In this work, we report 12 FBN1 mutations identified by temperature-gradient gel electrophoresis screening of exons 24–40 in 127 individuals with Marfan syndrome or related disorders. The data reported here, together with other published reports, document a significant clustering of mutations in exons 24–32. Although all reported mutations associated with neonatal Marfan syndrome and the majority of point mutations associated with atypically severe presentations have been found in exons 24–32, mutations associated with classic Marfan syndrome occur in this region as well. It is not possible to predict whether a given mutation in exons 24–32 will be associated with classic, atypically severe, or neonatal Marfan syndrome.

[1]  J. Clayton-Smith,et al.  Evolving phenotype of Marfan’s syndrome , 1997, Archives of disease in childhood.

[2]  B. Sykes,et al.  Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome. , 1993, Human molecular genetics.

[3]  M. Karck,et al.  Identification of 9 novel FBN1 mutations in German patients with Marfan syndrome , 1999, Human mutation.

[4]  H. Dietz,et al.  Fabrillin (FBN1) mutations in Marfan syndrome , 1992, Human mutation.

[5]  L. Lerman,et al.  Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. , 1987, Methods in enzymology.

[6]  P. Byers,et al.  Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene. , 1996, American journal of medical genetics.

[7]  P. Robinson,et al.  The molecular genetics of Marfan syndrome and related microfibrillopathies , 2000, Journal of medical genetics.

[8]  C. Hayward,et al.  Fibrillin‐1 mutations in Marfan syndrome and other type‐1 fibrillinopathies , 1997, Human mutation.

[9]  L. Peltonen,et al.  Recurrence of Marfan syndrome as a result of parental germ-line mosaicism for an FBN1 mutation. , 1999, American journal of human genetics.

[10]  B. Giusti,et al.  A major involvement of the cardiovascular system in patients affected by Marfan syndrome: novel mutations in fibrillin 1 gene. , 1997, Journal of molecular and cellular cardiology.

[11]  M. Passos-Bueno,et al.  Identification of 8 new mutations in Brazilian families with Marfan syndrome , 1999, Human mutation.

[12]  H. Dietz,et al.  A molecular approach to the stratification of cardiovascular risk in families with Marfan's syndrome. , 1994, The New England journal of medicine.

[13]  C. Detter,et al.  A novel mutation in the neonatal region of the fibrillin (FBN)1 gene associated with a classical phenotype of Marfan syndrome (MfS). Mutations in brief no. 163. Online. , 1998 .

[14]  James M. Wilson,et al.  Regulated Gene Expression in Gene Therapy , 2001, Annals of the New York Academy of Sciences.

[15]  W. Cole,et al.  Alternative splicing of exon 37 of FBN1 deletes part of an ‘eight‐cysteine’ domain resulting in the Marfan syndrome , 1999, Clinical genetics.

[16]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[17]  H. Dietz,et al.  Clustering of fibrillin (FBN1) missense mutations in Marfan syndrome patients at cysteine residues in EGF‐like domains , 1992, Human mutation.

[18]  R E Pyeritz,et al.  Revised diagnostic criteria for the Marfan syndrome. , 1996, American journal of medical genetics.

[19]  H. Dietz,et al.  Multiple molecular mechanisms underlying subdiagnostic variants of Marfan syndrome. , 1998, American journal of human genetics.

[20]  T. Rantamäki,et al.  Acute Mitral Regurgitation Due to Chordal Rupture in a Patient with Neonatal Marfan Syndrome Caused by a Deletion in Exon 29 of the FBN1 Gene , 1999, Pediatric Cardiology.

[21]  D. Sillence,et al.  International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986. , 1988, American journal of medical genetics.

[22]  F. Spencer,et al.  Revised genomic organization of FBN1 and significance for regulated gene expression. , 1999, Genomics.

[23]  P. Robinson,et al.  Clustering of mutations associated with mild Marfan-like phenotypes in the 3' region of FBN1 suggests a potential genotype-phenotype correlation. , 2000, American journal of medical genetics.

[24]  R. Pyeritz.  The Marfan syndrome. , 1986, American family physician.

[25]  L. Peltonen,et al.  Two novel fibrillin‐1 mutations resulting in premature termination codons but in different mutant transcript levels and clinical phenotypes , 1998, Human mutation.

[26]  P. Robinson,et al.  Bipolar clamping improves the sensitivity of mutation detection by temperature gradient gel electrophoresis , 1998, Electrophoresis.

[27]  L. Peltonen,et al.  Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome , 1994, Nature Genetics.

[28]  R E Pyeritz,et al.  Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. , 1995, American journal of human genetics.

[29]  L. Adès,et al.  Preferential pre-mRNA utilisation of an upstream cryptic 5' splice site created by a single base deletion mutation in exon 37 of the FBN-1 gene. , 1998, European journal of biochemistry.

[30]  D. Milewicz,et al.  Clustering of FBN2 mutations in patients with congenital contractural arachnodactyly indicates an important role of the domains encoded by exons 24 through 34 during human development. , 1998, American journal of medical genetics.

[31]  P. Handford,et al.  Defective calcium binding to fibrillin-1: consequence of an N2144S change for fibrillin-1 structure and function. , 1999, Journal of molecular biology.

[32]  U. Francke,et al.  Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. , 1999, American journal of human genetics.

[33]  U. Francke,et al.  Mutant fibrillin-1 monomers lacking EGF-like domains disrupt microfibril assembly and cause severe marfan syndrome. , 1996, Human molecular genetics.

[34]  G. Pals,et al.  Clinical, pathological and molecular genetic findings in a case of neonatal Marfan syndrome , 1999, Acta paediatrica.

[35]  Rocco,et al.  Abnormal morphology of fibrillin microfibrils in fibroblast cultures from patients with neonatal Marfan syndrome. , 1995, The American journal of pathology.

[36]  P. Robinson,et al.  Novel exon skipping mutation in the fibrillin‐1 gene: Two ‘hot spots’ for the neonatal Marfan syndrome , 1999, Clinical genetics.

[37]  P. Byers,et al.  Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. , 1992, The Journal of clinical investigation.

[38]  P. Handford,et al.  Solution structure of the transforming growth factor β‐binding protein‐like module, a domain associated with matrix fibrils , 1997, The EMBO journal.

[39]  U. Francke,et al.  A Gly1127Ser mutation in an EGF-like domain of the fibrillin-1 gene is a risk factor for ascending aortic aneurysm and dissection. , 1995, American journal of human genetics.